GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Hold” by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given a consensus rating of “Hold” by the fifteen ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $3.7708.

A number of brokerages have recently issued reports on GDRX. Leerink Partners reiterated an “outperform” rating and set a $3.00 price target on shares of GoodRx in a research report on Thursday, February 26th. The Goldman Sachs Group reiterated a “neutral” rating and set a $3.50 price target on shares of GoodRx in a research report on Friday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GoodRx in a research report on Friday, February 27th. Jefferies Financial Group downgraded GoodRx to a “hold” rating in a research report on Thursday, January 22nd. Finally, Citigroup dropped their price target on GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, March 3rd.

GoodRx Stock Down 5.3%

Shares of NASDAQ GDRX opened at $2.69 on Wednesday. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The business has a 50-day simple moving average of $2.25 and a two-hundred day simple moving average of $2.56. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The company has a market cap of $921.51 million, a P/E ratio of 44.84, a P/E/G ratio of 1.96 and a beta of 1.54.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The business had revenue of $194.01 million during the quarter, compared to the consensus estimate of $185.40 million. During the same quarter last year, the company earned $0.09 EPS. The firm’s revenue was down 4.4% compared to the same quarter last year. Research analysts anticipate that GoodRx will post 0.15 earnings per share for the current fiscal year.

Institutional Trading of GoodRx

A number of large investors have recently modified their holdings of GDRX. AQR Capital Management LLC boosted its position in shares of GoodRx by 124.4% during the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock valued at $1,245,000 after acquiring an additional 156,482 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of GoodRx by 7.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock valued at $3,455,000 after acquiring an additional 54,783 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of GoodRx during the 1st quarter valued at about $370,000. Creative Planning purchased a new position in shares of GoodRx during the 2nd quarter valued at about $93,000. Finally, Cetera Investment Advisers purchased a new position in shares of GoodRx during the 2nd quarter valued at about $50,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.